


Supplementary Information


Spinal cord injury causes chronic bone marrow failure

Carpenter et al.

Contents:
Supplementary Figures 1-2
Supplementary Table 1



Supplementary Figure 1. Supplemental data demonstrating flow cytometry panels. **a)** All flow cytometry panels identified live single cells using eFluor780 fixable viability dye or DAPI and forward/side scatter properties. **b)** Gating strategy to detect LSK and c-Kit⁺ cells from C57BL/6 mouse bone marrow and spleen in Figs. 1d-f; 2b-i; 3d,e; 6f-g. Live HSPCs were gated based on low expression of mature hematopoietic lineage markers and single positive for c-Kit (c-Kit⁺ cells) or double positive for c-Kit and Sca-1 (LSK cells). DNA content analysis with DAPI reveals cells in S-G2-M phases of the cell cycle, indicating proliferation. **c)** Gating strategy to identify LSK subsets, including MPP4s (CD135⁺), MPP3s (CD135⁻/48⁺/150⁻), MPP2s (CD135⁻/48⁺/150⁺), ST-HSCs (CD135⁻/48⁻/150⁻), and LT-HSCs (CD135⁻/48⁻/150⁺) in Fig. 2. **d)** Gating strategy to identify hCD34^{hi}/hCD38^{low} human HSPCs using fluorescently labeled human lineage, CD34, and CD38 antibodies in Fig. 3d. **e)** Gating strategy identifying immature (B220^{low}) and mature (B220^{hi}) B cell populations in bone marrow related to Fig. 5c-e. After isolating PreProB cells (CD43⁺/CD24^{low}), B220^{hi} bone marrow B cells were confirmed to be enriched for IgM⁺ transitional (subset 3) and IgM⁺/IgD⁺ mature (subset 4) B cells. B220^{low} bone marrow B cells were enriched for IgM⁻ ProB and PreB (subset 1) and IgM^{low} immature (subset 2) B cells.



Supplementary Figure 2. Supplemental data for competitive repopulating unit (CRU) experiments. **a**) CRU assay experimental design. **b**) flow cytometry gating strategy to identify single cells labeled with CD45.2 (from donor mouse groups) or CD45.1 (from BoyJ mice). **c**) Percent donor engraftment in spleen 19 weeks after primary transplantation. **d**) Total white blood cell (WBC) and red blood cell (RBC) counts from 4-16 weeks after primary transplantation. **e**) Composition of donor (C57 BL/6, CD45.2) WBCs 19 weeks after transplantation. **f**) Percent donor engraftment in spleen 25 weeks after secondary transplantation. **g**) Total white blood cell (WBC) and red blood cell (RBC) counts from 4-20 weeks after secondary transplantation. **h**) Total numbers of donor WBCs from 4-20 weeks after secondary transplantation. All data are mean \pm SEM, 2-way ANOVA with repeated measures (d,g,h) and 2-sample t-test (c,e,f); n=5/group in c-h. Dotted lines represent averaged data from BoyJ mice transplanted with naive C57 BL/6 bone marrow; Lam = laminectomy (sham-injury). Source data are provided as a Source Data file.

Supplementary Table 1. Primers for RT-qPCR

Gene Product	Forward Primer 5' to 3'	Reverse Primer 5' to 3'
IL1 β	CAGGCTCCGAGATGAACAAC	GGTGGAGAGCTTTCAGCTCATAT
TNF α	GTGATCGGTCCCCAAAGG	GGTCTGGGCCATAGAACTGATG
TGF β	TGAGTGGCTGTCTTTTGACGTC	TTCATGTCATGGATGGTGCC
CXCR4	TTACCCCGATAGCCTGTGGA	CAGGAGAGGATGACGATGCC
CXCL12	CAGACAAGTGTGTGCATTGACCC	CCTTTGGGCTGTTGTGCATTAC
CCL2	AACCTGGATCGGAACCAAATG	AAGTGCTTGAGGTGGTTGTGG
18S	TTCGGAAGTGAAGCCATGAT	TTTCGCTCTGGTCCGTCTTG